INS and Insulin resistance: There is significant improvement in the median level of HbA1c (8.0 vs 8.2%, p = 0.04), median insulin levels (7.5 vs 9.9 μIU/mL, p = 0.03), and homeostasis model assessment-estimated insulin resistance (HOMA.IR) (2.5 vs 2.9, p = 0.002) in group C (high dose) after three months when compared with the baseline value, however, there was no significant changes in FBS level.